Patents by Inventor Julie A. Wurster

Julie A. Wurster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
    Publication number: 20050228036
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: July 6, 2004
    Publication date: October 13, 2005
    Inventors: Steven Andrews, Julie Wurster, Clarence Hull
  • 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
    Publication number: 20040198720
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: February 20, 2004
    Publication date: October 7, 2004
    Inventors: Steven W. Andrews, Julie A. Wurster, Edward H. Wang, Thomas Malone
  • Kinase inhibitors for the treatment of disease
    Publication number: 20040198802
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: April 20, 2004
    Publication date: October 7, 2004
    Applicant: Allergan, Inc.
    Inventors: Steven W. Andrews, Michael E. Garst, Xialing Guo, Jonathan J. Hebert, Thomas Malone, Julie A. Wurster, Clarence Eugene Hull
  • 3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
    Patent number: 6765012
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: July 20, 2004
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Julie A. Wurster, Edward H. Wang, Thomas Malone
  • Kinase inhibitors for the treatment of disease
    Patent number: 6747025
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell poliferation.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: June 8, 2004
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Michael E. Garst, Xialing Guo, Jonathan J. Hebert, Thomas Malone, Julie A. Wurster, Clarence Eugene Hull, III
  • KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20040102509
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: March 13, 2003
    Publication date: May 27, 2004
    Applicant: Allergan, Inc.
    Inventors: Steven W. Andrews, Michael E. Garst, Xialing Guo, Jonathan J. Hebert, Thomas Malone, Julie A. Wurster, Clarence Eugene Hull
  • (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
    Publication number: 20040019098
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: April 1, 2003
    Publication date: January 29, 2004
    Applicant: Allergan, Inc.
    Inventors: Steven W. Andrews, Xialing Guo, Zhen Zhu, Clarence E. Hull, Julie A. Wurster, Shimiao Wang, Edward H. Wang, Thomas Malone
  • 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
    Publication number: 20030225152
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: September 27, 2002
    Publication date: December 4, 2003
    Inventors: Steven W. Andrews, Julie A. Wurster, Clarence E. Hull,
  • 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
    Publication number: 20030199478
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: September 27, 2002
    Publication date: October 23, 2003
    Inventors: Steven W. Andrews, Julie A. Wurster, Edward H. Wang, Thomas Malone
  • 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
    Publication number: 20030130328
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: September 26, 2002
    Publication date: July 10, 2003
    Inventors: Steven W. Andrews, Julie A. Wurster
  • 3-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
    Patent number: 6559173
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: September 26, 2002
    Date of Patent: May 6, 2003
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Julie A. Wurster
  • (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
    Patent number: 6541504
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: April 3, 2002
    Date of Patent: April 1, 2003
    Assignee: Allergan Sales, LLC
    Inventors: Steven W. Andrews, Julie A. Wurster, Clarence E. Hull, III, Edward H. Wang, Thomas Malone, Xialing Guo, Zhen Zhu
  • One vessel stereoselective glycosylation of purines and pyrimidines
    Patent number: 5602245
    Abstract: A process for the preparation of 2',3' dideoxynucleosides, 2'-deoxynucleosides, and 2',3'-dideoxy-2',3'-didehydronucleosides is provided that includes the synchronous addition of a stereoselecting moiety (a directing group) and a protected purine or pyrimidine base to 5-(S)-6-(protected-oxy)-4,5-dihydrofuran in the presence of a Lewis acid. This one vessel reaction eliminates the need to separately prepare and purify a 2'-substituted ribose derivative that in a second step is condensed with a purine or pyrimidine base. The process can be easily modified to increase the stereoselectivity of formation of the .beta.-anomeric nucleoside as necessary.
    Type: Grant
    Filed: November 4, 1992
    Date of Patent: February 11, 1997
    Assignee: Emory University
    Inventors: Julie Wurster, Dennis C. Liotta, Jianying Wang, Lawrence J. Wilson